CONTEXT: Pituitary stalk interruption represents a frequent feature of congenital hypopituitarism, but only rare cases have been assigned to a known genetic cause. OBJECTIVE: Using a candidate gene approach, we tested several genes as potential causes of hypopituitarism with pituitary stalk interruption. We hypothesized that ectopic posterior pituitary may be a consequence of defective neuronal axon projections along the pituitary stalk or defective angiogenesis of hypophyseal portal circulation. Considering the role of the prokineticin 2 pathway in angiogenesis and neuronal migration, we screened PROK2 and PROKR2 genes. DESIGN: PROK2 and PROKR2 and all genes previously known to be involved in hypopituitarism with pituitary stalk interruption (LHX4, HESX1, OTX2, and SOX3) were screened in 72 index cases with pituitary stalk interruption syndrome from the GENHYPOPIT database. In vitro studies were performed to assess the functional consequences of allelic variants. RESULTS: We identified two heterozygous PROKR2 mutations (p.Leu173Arg and p.Arg85His) previously reported in isolated hypogonadotroph hypogonadism and a novel PROKR2 variant (p.Ala51Thr) that, in contrast with both other mutations, did not impair receptor signaling activity. Three allelic variants of HESX1 were identified: the heterozygous p.Phe156Ser and the homozygous p.Arg109X mutations were functionally deleterious, whereas p.Ser67Thr was found as a rare allelic variant in association with p.Arg85His PROKR2 mutation in the same patient. CONCLUSIONS: We report PROKR2 variants in congenital hypopituitarism with pituitary stalk interruption, suggesting a potential role of the prokineticin pathway in pituitary development.
CONTEXT: Pituitary stalk interruption represents a frequent feature of congenital hypopituitarism, but only rare cases have been assigned to a known genetic cause. OBJECTIVE: Using a candidate gene approach, we tested several genes as potential causes of hypopituitarism with pituitary stalk interruption. We hypothesized that ectopic posterior pituitary may be a consequence of defective neuronal axon projections along the pituitary stalk or defective angiogenesis of hypophyseal portal circulation. Considering the role of the prokineticin 2 pathway in angiogenesis and neuronal migration, we screened PROK2 and PROKR2 genes. DESIGN:PROK2 and PROKR2 and all genes previously known to be involved in hypopituitarism with pituitary stalk interruption (LHX4, HESX1, OTX2, and SOX3) were screened in 72 index cases with pituitary stalk interruption syndrome from the GENHYPOPIT database. In vitro studies were performed to assess the functional consequences of allelic variants. RESULTS: We identified two heterozygous PROKR2 mutations (p.Leu173Arg and p.Arg85His) previously reported in isolated hypogonadotroph hypogonadism and a novel PROKR2 variant (p.Ala51Thr) that, in contrast with both other mutations, did not impair receptor signaling activity. Three allelic variants of HESX1 were identified: the heterozygous p.Phe156Ser and the homozygous p.Arg109X mutations were functionally deleterious, whereas p.Ser67Thr was found as a rare allelic variant in association with p.Arg85HisPROKR2 mutation in the same patient. CONCLUSIONS: We report PROKR2 variants in congenital hypopituitarism with pituitary stalk interruption, suggesting a potential role of the prokineticin pathway in pituitary development.
Authors: Zaid Mohsen; Hosung Sim; David Garcia-Galiano; Xingfa Han; Nicole Bellefontaine; Thomas L Saunders; Carol F Elias Journal: Brain Struct Funct Date: 2017-06-14 Impact factor: 3.270
Authors: Ravikumar Balasubramanian; Sheena Chew; Sarah E MacKinnon; Peter B Kang; Caroline Andrews; Wai-Man Chan; Elizabeth C Engle Journal: J Clin Endocrinol Metab Date: 2015-01-05 Impact factor: 5.958
Authors: Ender Karaca; Ramazan Buyukkaya; Davut Pehlivan; Wu-Lin Charng; Kursat O Yaykasli; Yavuz Bayram; Tomasz Gambin; Marjorie Withers; Mehmed M Atik; Ilknur Arslanoglu; Semih Bolu; Serkan Erdin; Ayla Buyukkaya; Emine Yaykasli; Shalini N Jhangiani; Donna M Muzny; Richard A Gibbs; James R Lupski Journal: J Clin Endocrinol Metab Date: 2015-01 Impact factor: 5.958
Authors: Qing Fang; Akima S George; Michelle L Brinkmeier; Amanda H Mortensen; Peter Gergics; Leonard Y M Cheung; Alexandre Z Daly; Adnan Ajmal; María Ines Pérez Millán; A Bilge Ozel; Jacob O Kitzman; Ryan E Mills; Jun Z Li; Sally A Camper Journal: Endocr Rev Date: 2016-11-09 Impact factor: 19.871
Authors: Brent S Abel; Natalie D Shaw; Jenifer M Brown; Judith M Adams; Teresa Alati; Kathryn A Martin; Nelly Pitteloud; Stephanie B Seminara; Lacey Plummer; Duarte Pignatelli; William F Crowley; Corrine K Welt; Janet E Hall Journal: J Clin Endocrinol Metab Date: 2013-01-22 Impact factor: 5.958
Authors: F Castinetti; R Reynaud; M-H Quentien; N Jullien; E Marquant; C Rochette; J-P Herman; A Saveanu; A Barlier; A Enjalbert; T Brue Journal: J Endocrinol Invest Date: 2014-09-09 Impact factor: 4.256
Authors: Mark J McCabe; Carles Gaston-Massuet; Louise C Gregory; Kyriaki S Alatzoglou; Vaitsa Tziaferi; Oualid Sbai; Philippe Rondard; Koh-hei Masumoto; Mamoru Nagano; Yasufumi Shigeyoshi; Marija Pfeifer; Tony Hulse; Charles R Buchanan; Nelly Pitteloud; Juan-Pedro Martinez-Barbera; Mehul T Dattani Journal: J Clin Endocrinol Metab Date: 2013-02-05 Impact factor: 5.958